In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

The Babylonians used separate combinations of two symbols to represent every single number from 1 to 59. That sounds pretty confusing, doesn’t it? Our decimal system seems simple by comparison, with ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Good programmers need to create code that efficiently solves problems, using various methods. A ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

The big picture: Java stands as one of the enduring pillars of the software world. The programming language was released by Sun Microsystems on May 23, 1995, and so far has weathered the shifting ...

As you know, Google is okay with linking its AI Overviews back to more Google Search results. But is Google okay with linking the same query, to the same query, over and over again, through the AI ...

Recursion announced that the UK Medicines and Healthcare Products Regulatory Agency has cleared a clinical trial application for a Phase 1 clinical trial of REC-3565, a potential best-in-class MALT1 ...